Zentek's ZenGUARD(TM) Enhanced Air Filters Now Available for Direct Procurement by All Federal Departments and Agencies

Zentek announced that its ZenGUARD Enhanced Air Filters have been placed on the Innovative Solutions Canada (ISC) Pathway to Commercialization (PTC) source list, following validation by the National Research Council (NRC). The listing establishes Zentek as an exclusive supplier to the Government of Canada for a three‑year period; any federal department or agency may now purchase the filters directly. Testing documented a ~5× increase in viral filtration efficiency over a standard MERV 8 filter with no airflow or energy penalty, and ASHRAE 52.2/241 compliance.

• Context: The milestone is the expected culmination of a multi‑year ISC engagement, with the Health Canada regulatory exemption (May 6, 2026) already having removed the main market‑entry barrier. The achievement was therefore well‑flagged, and the stock had already jumped from ~$0.69 to $1.17 in the sessions surrounding that prior catalyst.
• Incremental news: The formal listing locks in a three‑year, exclusive federal supply framework and publicly validates performance claims with NRC backing. This substantially de‑risks the health‑care/institutional revenue channel in Canada and provides a reference for other government buyers.
• Financial materiality: No revenue figures are disclosed. While the PTC listing improves the sales pipeline, the actual volume and margin are unknown. Given the lack of concrete financial guidance, the event is positive but within the expected sequence of commercial steps.
• Strategic angle: The news reinforces the ZenGUARD commercialization pathway and may accelerate provincial/municipal and international procurement. It also strengthens the company’s case for similar U.S. or NATO procurement programs.
• Overall: The announcement does not introduce genuinely new, unexpected information; it is the logical next step. Thus, the incremental impact is positive but routine.

• Core platforms: (1) ZenGUARD – graphene‑coated air‑filter media that increase viral filtration efficiency without increasing pressure drop; sold as drop‑in products for existing HVAC systems. (2) Albany Graphite – 100%‑owned Albany Graphite Project in Ontario; boasts ultra‑high purity (5N+, 99.9992% C, low boron) suitable for nuclear reactors, defence, and premium batteries; a new PEA is underway. (3) Triera Biosciences – aptamer‑based diagnostics and therapeutics platform, focused on infectious disease (influenza) and offering CRO services.
• Flagship project: Albany Graphite is the highest‑potential asset, targeting the underserved Western nuclear/defence graphite supply chain. The deposit has 22.9 Mt Indicated at 4.07% Cg and 13.1 Mt Inferred at 2.87% Cg (2023 resource). A PEA is expected in Summer 2026.
• Other assets: ZenGUARD has achieved federal procurement status; Triera is progressing with government‑funded influenza programs and a new CRO service line.